Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects
NCT03189589
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG:
GSK2269557 500 µg
DRUG:
GSK2269557 750 µg
Sponsor
GlaxoSmithKline